AstraZeneca- Datroway J-Code
AstraZeneca- Datroway J-Code
Information available listed below as well as information on the new Datroway J-Code:
We now have a Pre-approval Information Exchange (PIE) presentation available for SERENA-6 our Phase III randomized trial to assess switching from AI + CDK4/6 inhibitor to camizestrant + CDK4/6 inhibitor in patients with HR+/HER2- locally advanced and metastatic breast cancer with emergent ESR1 mutations. Camizestrant is an investigational product for this trial.
The most recent PIE presentation is for Serena-6 and below you will find the additional PIE presentations that you may be interested in. If there is interest, I can have them covered in one call or we could schedule individual calls (30 min in length). One item that I could use some clarification on is whether you have had our clinical reviews for your teams. With so many approvals in the past years, many accounts have requested clinical reviews which provides a pipeline presentation for our Oncology portfolio. The focus is typically tailored to provide a high-level overview and then streamlined to what is expected to be approved in the next 6-9 months. 2026 will bring more anticipated growth for our franchises with an expected 16 approvals.
Additional PIE presentations available:
MATTERHORN Trial: A phase III global study of perioperative treatment for resectable gastric and gastroesophageal adenocarcinomas using durvalumab with FLOT chemotherapy. Durvalumab combined with FLOT is investigational for these indications.
AMPLIFY Trial: A randomized, multicenter, open-label, phase III study in adult patients with previously untreated CLL to compare the efficacy and safety of acalabrutinib in combination with venetoclax, with and without obinutuzumab, compared to investigator’s choice of chemoimmunotherapy.
Destiny Breast-09 Trial: Fam-Trastuzumab Deruxtecan-nxki is being investigated for the treatment of adult patients with unresectable or metastatic Her2+ breast cancer in the first line setting in combination with pertuzumab, who have not received a piror anti-HER2 regimen for metastatic disease.
